Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study
Roberta Caputo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Laura Amaducci(Ospedale degli Infermi), Vincenzo Montesarchio(CTO Hospital), Rosalba Torrisi(IRCCS Humanitas Research Hospital), Andrea Sbrana(University of Pisa), Ida Paris(Agostino Gemelli University Polyclinic), Monica Giordano(Ospedale Sant'Anna), Alessio Schirone, Marina Elena Cazzaniga(Azienda Ospedaliera San Gerardo), Giuseppina Cilenti(Casa Sollievo della Sofferenza), Alessandra Fabi(Agostino Gemelli University Polyclinic), Luigi Celio, Sabino De Placido, Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), Erminio Bonizzoni(University of Milan), Valentina Guarneri(Istituto Oncologico Veneto), Elena Collovà(Aziende Socio Sanitarie Territoriale Ovest Milanese)
Cited by 12
Related Papers
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830